Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC.LXRX · Entity 4970 | Director | June 03, 2026 | June 04, 2026 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | 10% owner | December 11, 2025 | February 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LEXICON PHARMACEUTICALS, INC.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,995,498 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Exercise / conversion · Acquired 89,312 · Balance 1,995,498 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-03 · Exercise / conversion · Disposed 89,312 · Balance 0 F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2: Each restricted stock unit represents a contingent right to receive one share of common stock. |
| Common StockSEC Table I · non-derivative | IndirectBy Avicenna Life Sci Master Fund LP and related parties | 1,538,462 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,538,462 |
| Common StockSEC Table I · non-derivative | IndirectBy Invus Public Equities, L.P. and related parties | 7,362,368 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,362,368 |
| Common StockSEC Table I · non-derivative | IndirectBy Invus US Partners, LLC and related parties | 5,451,204 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,451,204 |
| Common StockSEC Table I · non-derivative | IndirectBy Invus, L.P. and related parties | 35,402,689 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 35,402,689 |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
Scholar Rock Holding Corp
Report date December 11, 2025 · Filed February 06, 2026
Jointly reported with Invus Global Management, LLC, Siren, L.L.C.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,825,013 |
Reported balance
After 2025-12-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-11 · Other · Acquired 1,575,008 · Balance 10,825,013 F1: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.35 · Expires 2025-12-31 | Direct | 0 |
Reported balance
After 2025-12-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-11 · Other · Disposed 1,575,008 · Balance 0 F1: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. The managing member of Invus Public Equities Advisors, LLC is Invus Global Management, LLC. The managing member of Invus Global Management, LLC is Siren, L.L.C. The managing member of Siren, L.L.C. is Mr. Raymond Debbane.
F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Blue Buffalo Pet Products, Inc.
Report date April 24, 2018 · Filed April 24, 2018
Section 16 reporting ended · disclosed 2018-04-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-24 transaction · row 1
1 source rowRow 1 · 2018-04-24 · Disposition to issuer · Disposed 10,569 · Balance 0 F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 24, 2018, General Mills, Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Bravo Merger Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of February 22, 2018 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").
F2: At the effective time of the Merger, each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $40.00 in cash, without interest and after giving effect to any required withholding taxes.
CRESCENT BIOPHARMA, INC.
Report date August 07, 2024 · Filed August 09, 2024
Jointly reported with Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Siren, L.L.C., Invus Global Management, LLC
Section 16 reporting ended · disclosed 2024-08-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,317,565 |
Last balance in matching sequence
After 2024-08-08 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2024-08-07 · Sale · Disposed 61,488 · Balance 6,578,438 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Row 2 · 2024-08-08 · Sale · Disposed 260,873 · Balance 6,317,565 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C. F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Common Stock is held directly by Invus Public Equities, L.P. The general partner of Invus Public Equities, L.P. is Invus Public Equities Advisors, LLC. Invus Global Management, LLC is the managing member of Invus Public Equities Advisors, LLC. Siren, L.L.C. is the managing member of Invus Global Management, LLC. Mr. Raymond Debbane is the managing member of Siren, L.L.C.
F2: Each of the reporting persons (other than to the extent it directly holds securities reported herein), disclaims beneficial ownership of the securities held by the other reporting persons, except to the extent of such reporting person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Exchange Act, each of the reporting persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.175 to $0.1855 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.18 to $0.1978 per share, inclusive. The reporting persons undertake to provide to GlycoMimetics, Inc., any security holder of GlycoMimetics, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
WW INTERNATIONAL, INC.
Report date May 09, 2023 · Filed May 11, 2023
Section 16 reporting ended · disclosed 2023-05-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,387 |
Reported balance
After 2023-05-09 transaction · row 1
1 source rowRow 1 · 2023-05-09 · Grant · Acquired 835 · Balance 134,387 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 10, 2022 Filed Nov 15, 2022 22:26 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | PurchaseCommon Stock | 75,000 | $4.27 | $320,055.00 |
DisclosureSEC source: 0001209191-22-057075 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,432 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.205 to $4.36, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above. Read SEC document |
| October 03, 2022 Filed Oct 5, 2022 21:27 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 4,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-052828 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,432 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 20:48 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 147,390 | $2.50 | $368,475.00 |
DisclosureSEC source: 0000899243-22-028113 · doc4.xml · nonDerivative · entry 1 Invus US Partners LLC · CIK 0001839806 · Director · 10% owner Ulys, L.L.C. · CIK 0001340098 · Director · 10% owner DEBBANE RAYMOND · CIK 0001053890 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,451,204 F1 · kind: Pursuant to a purchase agreement dated July 27, 2022, between Invus US Partners LLC and the Issuer, on August 5, 2022, Invus US Partners LLC purchased an additional 147,390 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock. F2 · ownership.nature: These securities are directly held by Invus US Partners LLC F4 · ownership.nature: Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 20:13 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 982,600 | $2.50 | $2,456,500.00 |
DisclosureSEC source: 0001127602-22-020005 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Invus US Partners LLC Disclosed balance after: 5,303,814 Read SEC document |
| August 01, 2022 Filed Aug 1, 2022 20:15 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 982,600 | $2.50 | $2,456,500.00 |
DisclosureSEC source: 0000899243-22-027157 · doc4.xml · nonDerivative · entry 1 Invus US Partners LLC · CIK 0001839806 · Director · 10% owner Ulys, L.L.C. · CIK 0001340098 · Director · 10% owner DEBBANE RAYMOND · CIK 0001053890 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 5,303,814 F1 · kind: On July 27, 2022, Invus US Partners LLC entered into a purchase agreement with the Issuer pursuant to which Invus US Partners LLC agreed to purchase 982,600 shares of common stock, $0.001 par value per share (the "Issuer Common Stock") of the Issuer at a price of $2.50 per share. The purchase closed on August 1, 2022. F2 · ownership.nature: These securities are directly held by Invus US Partners LLC F4 · ownership.nature: Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C. F5 · ownership.nature: Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose. Read SEC document |
| July 04, 2022 Filed Jul 6, 2022 20:31 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 2,745 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-041132 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,837 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| May 21, 2022 Filed May 23, 2022 20:14 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 9,302 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-015368 · form4.xml · derivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,302 Underlying: Common Stock · 9,302 shares Expires not disclosed F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| May 21, 2022 Filed May 23, 2022 20:14 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 14,402 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0001127602-22-015368 · form4.xml · derivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,402 Underlying: Common Stock · 14,402 shares Expires 2032-05-21 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 30, 2022 Filed May 2, 2022 20:14 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 4,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012827 · form4.xml · derivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,024 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 30, 2022 Filed May 2, 2022 20:14 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 4,024 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012827 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 331,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2022 Filed Apr 6, 2022 20:15 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 1,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023464 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,092 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:16 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 1,179 | $15.90 | $18,746.10 |
DisclosureSEC source: 0001209191-22-001654 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,295 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:07 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 998 | $18.78 | $18,742.44 |
DisclosureSEC source: 0001209191-21-059807 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,116 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| July 05, 2021 Filed Jul 7, 2021 20:20 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 523 | $35.84 | $18,744.32 |
DisclosureSEC source: 0001209191-21-045786 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,118 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| April 30, 2021 Filed May 3, 2021 21:03 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 6,475 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001127602-21-014963 · form4.xml · derivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,475 Underlying: Common Stock · 6,475 shares Expires 2031-04-30 F3 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| April 30, 2021 Filed May 3, 2021 21:03 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 4,024 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014963 · form4.xml · derivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,024 Underlying: Common Stock · 4,024 shares Expires not disclosed F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 24, 2021 Filed Apr 27, 2021 20:47 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 10,638 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014519 · form4.xml · derivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,638 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 24, 2021 Filed Apr 27, 2021 20:47 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 10,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014519 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:17 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 609 | $30.77 | $18,738.93 |
DisclosureSEC source: 0001209191-21-025862 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,595 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:16 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 724 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002025 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,986 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| September 28, 2020 Filed Sep 30, 2020 21:47 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 996 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052484 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,262 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 20:09 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 740 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-039712 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,266 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| April 26, 2020 Filed Apr 27, 2020 20:45 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionRestricted Stock Units · Derivative | 3,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-014563 · form4.xml · derivative · entry 5 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock. F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 26, 2020 Filed Apr 27, 2020 20:45 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | Exercise / conversionCommon Stock | 3,466 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-014563 · form4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 20:45 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantRestricted Stock Units · Derivative | 10,638 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-014563 · form4.xml · derivative · entry 4 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,638 Underlying: Common Stock · 10,638 shares Expires not disclosed F2 · derivative.exercise_date: Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| April 24, 2020 Filed Apr 27, 2020 20:45 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | GrantStock Option (Right to Buy) · Derivative | 18,115 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001127602-20-014563 · form4.xml · derivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,115 Underlying: Common Stock · 18,115 shares Expires 2030-04-24 F1 · derivative.exercise_date: Option vests with respect to one third of the shares subject to the option on each of the first three anniversaries of the grant date. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 20:16 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 1,128 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-022098 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,526 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| December 30, 2019 Filed Jan 2, 2020 21:11 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 469 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000255 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,398 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 20:59 UTC | WW INTERNATIONAL, INC. WW · Entity 6479 | GrantCommon Stock | 514 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051799 · doc4.xml · nonDerivative · entry 1 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,929 F1 · shares: The shares listed represent shares of Common Stock subject to transfer restrictions. Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 3,400 | $2.80 | $9,520.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 22 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,417 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 7,500 | $2.79 | $20,925.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 21 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,017 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 3,900 | $2.78 | $10,842.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 20 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,517 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 12,400 | $2.77 | $34,348.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 19 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,617 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 4,500 | $2.76 | $12,420.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 18 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 286,217 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 6,853 | $2.75 | $18,845.75 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 17 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,717 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 1,900 | $2.74 | $5,206.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 16 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,864 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 11,100 | $2.73 | $30,303.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 15 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,964 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 8,082 | $2.72 | $21,983.04 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 14 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,864 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 6,443 | $2.71 | $17,460.53 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 13 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,782 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 400 | $2.70 | $1,080.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 12 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,339 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 500 | $2.69 | $1,345.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 11 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,939 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 1,300 | $2.68 | $3,484.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 10 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,439 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 4,600 | $2.67 | $12,282.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 9 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,139 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 1,100 | $2.66 | $2,926.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 8 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,539 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 2,100 | $2.64 | $5,544.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 7 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,439 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 4,800 | $2.63 | $12,624.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 6 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,339 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 3,110 | $2.62 | $8,148.20 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 5 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,539 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 5,795 | $2.61 | $15,124.95 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 4 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,429 Read SEC document |
| September 16, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 3,990 | $2.60 | $10,374.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 3 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,634 Read SEC document |
| September 13, 2019 Filed Sep 17, 2019 21:36 UTC | LEXICON PHARMACEUTICALS, INC. LXRX · Entity 4970 | PurchaseCommon Stock | 400 | $2.47 | $988.00 |
DisclosureSEC source: 0001127602-19-028597 · form4.xml · nonDerivative · entry 2 DEBBANE RAYMOND · CIK 0001053890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,644 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.